The Dialysis Market: Size, Demand & Reimbursement

The global dialysis market is valued at approximately $120.75 billion in 2025 and is projected to reach $128.36 billion in 2026, expanding at a compound annual growth rate of around 6.3%, according to Precedence Research. A separate estimate from IMARC Group puts the 2025 figure at $125.8 billion, growing at 4.14% annually through 2034 to reach $181.2 billion, driven largely by favourable government reimbursement policy and expanding healthcare infrastructure in lower- and middle-income countries.

The US market on its own is worth $30.9 billion in 2025 and is forecast to reach $52.2 billion by 2034, a 6% CAGR, according to GMI Insights. That growth is a direct function of chronic kidney disease prevalence: diabetes and hypertension rates keep pushing more patients into end-stage renal disease (ESRD) every year, and unlike most healthcare categories, dialysis demand is close to inelastic. A patient in renal failure does not defer treatment the way they might defer an elective procedure.

That demand growth explains why DaVita Kidney Care and Fresenius Kidney Care together account for roughly 71.7% of all US dialysis treatments, with DaVita alone holding over 38% share in 2024. U.S. Renal Care is a distant third, and the remaining share is split between smaller regional chains, hospital-affiliated programmes, and independent clinics like Dialysis Clinic Inc. (DCI) and Satellite Healthcare. In Europe, Diaverum operates a similar network model across multiple countries. That concentration is precisely why a well-run independent clinic, positioned around a specific catchment area or a payer relationship the majors have not locked down, can still find a defensible niche.

Where Independent Clinics Actually Compete

Scale gives DaVita and Fresenius purchasing power on consumables and stronger footing in commercial payer negotiations that an independent clinic cannot match directly. What an independent clinic can offer instead is responsiveness: shorter appointment-scheduling flexibility, a medical director who is personally reachable to referring nephrologists, and a smaller, more consistent care team that patients on a three-times-weekly regimen for years come to trust. In markets where the two majors already operate near capacity, or where a specific hospital system prefers to refer to a physician-owned facility rather than a corporate chain, an independent clinic's business plan should lead with that referral relationship as its primary competitive asset rather than trying to compete with DaVita or Fresenius on price or scale.

For a business plan, the number that matters more than total market size is the reimbursement rate, because that single figure determines whether a new clinic is viable at all. We cover that in detail in the unit economics section below, but the short version is this: dialysis is a volume business with a fixed, government-set floor on price. Founders who understand that from day one build realistic plans. Founders who model commercial-insurance rates across their whole patient base almost always end up under-capitalised within the first 18 months.

Demand growth is not speculative. The core driver is chronic kidney disease progressing to end-stage renal disease, and the two biggest upstream causes, diabetes and hypertension, are both rising in prevalence across the US, UK, and most developed healthcare markets. That means a dialysis clinic's addressable population is set by regional disease prevalence and physician referral patterns rather than by marketing spend, which is unusual for a healthcare business and worth stating explicitly in a business plan's market sizing section: a founder should model their local nephrology referral base, not a national growth rate applied blindly to a local catchment area.

A second structural trend worth naming in any 2026 plan is the slow but steady shift toward home dialysis. CMS has spent several payment cycles building financial incentives, including the training add-on payment referenced in the unit economics section, to push more ESRD patients toward home hemodialysis and peritoneal dialysis rather than three-times-weekly in-centre visits. That shift does not eliminate demand for in-centre clinics, most patients are still clinically or logistically better suited to in-centre care, but it does mean a modern business plan should show at least a modest home training service line, both because CMS reimburses it and because it signals to a lender or CON reviewer that the applicant understands where the payment system is heading.

SBA & Lender Data for Dialysis Clinics

Dialysis clinics fall under NAICS code 621492 (Kidney Dialysis Centers), an industry the US Census Bureau reports generates over $20 billion annually. The SBA size standard for this code is a generous $47 million in average annual receipts, meaning the vast majority of independent clinics, including multi-site operators with several hundred patients, still qualify as a small business for SBA lending purposes.

The two SBA programmes most relevant to a new dialysis clinic are the 7(a) loan, typically used for working capital, leasehold improvements, and acquisitions, and the SBA 504 loan, built specifically for major fixed-asset purchases like dialysis machines, water treatment systems, and owner-occupied real estate. According to Crestmont Capital, both programmes offer below-market rates and repayment terms long enough to match the multi-year payback period of a dialysis station, and typical approval timelines run 30 to 90 days once a complete application package is submitted.

During the Paycheck Protection Program, 489 businesses classified under NAICS 621492 received a combined $117.99 million in PPP loans nationally, a rough proxy for how many small and mid-sized dialysis operators exist outside the DaVita/Fresenius duopoly and how much capital a lender is willing to commit per clinic. For a bespoke SBA-ready plan, our $1,000/£800 Bespoke Business Plan service builds the 5-year financial model most 7(a) and 504 underwriters expect to see, including a station-by-station capacity build and a payer-mix-adjusted revenue forecast.

In practice, a first-time dialysis founder rarely finances the whole project through a single instrument. A common structure we see in bespoke plans splits the capital stack three ways: an SBA 504 loan against the fixed assets (machines, water system, leasehold improvements), a smaller SBA 7(a) facility or a bank line for working capital and the billing-lag reserve, and founder or physician-group equity covering the gap plus a contingency buffer. Lenders underwriting NAICS 621492 applicants will almost always ask for the CMS certification timeline and, where relevant, CON approval status as conditions precedent to funding, which is why sequencing those regulatory steps ahead of the loan application, rather than in parallel with it, tends to move the deal faster.

What It Actually Costs to Open a Dialysis Clinic

Startup costs for a dialysis center vary enormously depending on scope. A small satellite clinic added to an existing medical building can open for as little as $400,000, while a full ground-up standalone facility with a purpose-built water plant and isolation capability can run $1.5 million to $3 million or more, according to figures compiled by Business Plan Templates and Financial Models Lab. In the UK, an equivalent independent CQC-registered unit typically requires £320,000 to £1.9 million, an Avvale estimate scaled from the equivalent US facility spec, since UK-specific published cost data for independent dialysis units is limited.

Cost Breakdown (12-Station Clinic)

• Hemodialysis machines (12 stations, $15K–$25K/unit): $180,000–$300,000 (£140K–£235K)
• Facility build-out, specialised plumbing & HVAC: $500,000–$1,500,000 (£390K–£1.18M)
• Water purification and treatment system: ~$150,000 (~£118K)
• Emergency backup generator: ~$60,000 (~£47K)
• CMS/state licensing, survey and permit fees: $30,000–$50,000 (UK: £1,743 CQC fee + legal/consulting)
• Working capital reserve (payroll, supplies, billing lag): $1,121,000 minimum recommended reserve

Initial staff recruitment and training is easy to under-budget because it happens before any revenue arrives. A first-time clinic typically needs to recruit and train a charge nurse, several registered nurses, multiple patient care technicians, a biomedical technician (often contracted rather than employed), and administrative/billing staff, all before the CMS survey date, since surveyors expect a fully staffed facility during the certification visit rather than a plan to hire once patients arrive. Budgeting three to four months of pre-opening payroll on top of the equipment and facility figures above is a realistic planning assumption for most independent clinics.

That working capital figure surprises most first-time founders. Dialysis billing runs on a lag: claims to Medicare and commercial payers can take 30 to 90 days to reimburse, and staff still need paying every two weeks regardless. Undercapitalising this reserve is one of the fastest ways an otherwise well-run clinic runs into a cash crunch in its first year of operation.

Funding Routes

In the US, the SBA 7(a) and 504 loan programmes (detailed above) are the standard financing route, often combined with equipment-specific vendor financing from Fresenius Medical Care or Baxter directly. In the UK, the Start Up Loans scheme offers up to £25,000 at 6% fixed interest, which covers only a fraction of an independent unit's capital needs but can bridge working capital during the CQC registration window. Larger UK clinics typically combine bank asset finance for equipment with private or NHS-partnership capital for the facility itself. Similar structured lending exists in Canada through the BDC and in Australia through the major trading banks' healthcare finance divisions.

Site Selection & Real Estate

Site selection deserves its own line in the plan because it drives both the build-out cost and the patient acquisition model. Most dialysis patients cannot drive themselves post-treatment, so proximity to public transport, patient transport services, or a residential catchment within a 15-20 minute drive radius matters more than street-level visibility. Leasing a purpose-built medical shell inside an existing clinical building is almost always cheaper than converting retail or general office space, because the plumbing, electrical capacity, and ceiling height requirements for a water treatment loop are substantial. Founders comparing a lease against a purchase should model the CON or CMS survey timeline against the lease start date: paying rent on an empty facility for six to twelve months while awaiting certification is one of the most common unplanned costs in a first-year dialysis budget.

Equipment, Suppliers & Build-Out Checklist

Unlike most healthcare business plan pages, which list "medical equipment" as a single line item, lenders and CMS surveyors expect a dialysis plan to name specific systems and suppliers. Four vendors dominate the global equipment market:

• Fresenius Medical Care: the dominant vertically integrated supplier, spanning machines, dialysers, and consumables, and now owner of NxStage following its acquisition
• Baxter International: a leader in peritoneal dialysis and home-based systems; Baxter completed a $3.8 billion carve-out of its kidney-care arm (Vantive) to sharpen its focus on the category
• NxStage: now part of Fresenius, best known for its System One home hemodialysis unit
• B. Braun Melsungen: a broad portfolio spanning hemodialysis systems, consumables, and water treatment devices, popular with independent clinics negotiating outside the Fresenius/Baxter duopoly

Facility & Equipment Checklist

• Hemodialysis machines sized to station count and shift plan
• Reverse-osmosis water purification and distribution loop, tested to AAMI water quality standards
• Isolation station(s) for hepatitis B-positive or other infection-control-flagged patients
• Emergency backup generator sized to sustain a full treatment shift during a power outage
• Clinical waste management contract for sharps and biohazard disposal
• Electronic health record and dialysis-specific charting software (e.g. systems built on the CROWNWeb/CROWNWeb-successor CMS reporting standard)
• Point-of-care lab equipment for pre- and post-treatment bloodwork
• Dialysers, blood tubing sets, needles, and dialysate concentrate on a recurring supply contract
• Vascular access treatment chairs sized for multi-hour sessions

A plan that names these systems, and prices them against real vendor quotes rather than a rounded lump sum, reads as materially more credible to an SBA underwriter or a CON reviewer than a generic "$500K equipment budget" line. It also forces the founder to actually source quotes before opening, which surfaces lead-time and financing issues months earlier than discovering them at build-out.

Maintenance contracts deserve their own budget line too. Hemodialysis machines run continuously across three daily shifts, and a single unplanned outage can strand an entire treatment cohort mid-session, so most independent clinics carry a preventive maintenance contract directly with their equipment vendor rather than relying on in-house biomedical staff alone. Water system maintenance is even more critical: because the reverse-osmosis loop directly affects patient safety, most state surveyors and CQC inspectors treat water-quality testing logs as one of the first documents they request, and a lapsed maintenance contract is one of the fastest ways to trigger a conditional finding during survey.

On the software side, most US facilities report clinical and quality data to CMS through systems built around the CROWNWeb reporting standard and its successor platforms, and a founder should budget for staff training time on this reporting workflow separately from general EHR onboarding, since ESRD quality reporting carries its own payment-adjustment consequences under the ESRD Quality Incentive Program if submissions are late or incomplete.

Unit Economics: Revenue, Reimbursement & Margin

Dialysis is one of the few healthcare categories where the price is largely set by government policy rather than the market. The CY2025 Medicare ESRD Prospective Payment System (PPS) bundled base rate is $273.82 per treatment, up from $271.02 in CY2024, per the CMS final rule. That bundled rate now also includes oral-only renal dialysis drugs, a 2025 change that removes a previously separate billing category.

Commercial insurers pay dramatically more. A widely cited peer-reviewed analysis found commercial payers averaging roughly $1,041 per treatment compared with $248 for government insurance, a gap that compounds to roughly $148,722 a year for a privately insured patient versus $35,424 for a Medicare or Medicaid patient receiving the standard three-times-weekly regimen. Because the large majority of dialysis patients are covered by Medicare, Medicaid, or Medicare Advantage, blended clinic revenue lands much closer to the government rate than the commercial one.

Averaged across the whole payer mix, industry data puts clinic revenue at approximately $47,321 per patient per year, equivalent to roughly $331 per treatment blended. A 12-station clinic carrying a caseload of around 48 patients, achievable by running three shifts a day across the year, would therefore generate approximately $2.27 million in annual revenue. Net margin on that revenue typically runs 8% to 16% for independent operators: the large national chains report operating margins nearer the top of that range because of scale efficiencies in purchasing and back-office billing, while a standalone independent clinic more commonly lands in the 8-12% band until it builds a multi-site referral network.

Additional revenue streams worth modelling separately include home dialysis training reimbursement (Medicare pays an add-on for training patients on home hemodialysis or peritoneal dialysis), acute kidney injury (AKI) treatment billed under a separate CMS payment track, and ancillary lab and pharmacy services where state scope-of-practice rules allow the clinic to bill directly rather than referring out.

On the cost side, staffing is by far the largest controllable expense, typically 45-55% of revenue for an independent clinic once nursing, patient care technicians, and a part-time medical director are all accounted for. Dialysis-specific consumables (dialysers, tubing sets, needles, and dialysate concentrate) typically run 15-20% of revenue, with facility costs (rent, utilities, water treatment maintenance) adding a further 10-15%. That leaves a fairly narrow band for administrative overhead and profit, which is exactly why the payer-mix assumption matters so much: a clinic that models an optimistic commercial share of 35% when the realistic figure for its local population is closer to 15% will show a healthy margin on paper that never materialises once real claims start coming in.

A useful sanity check for a first business plan is to build the model bottom-up from a single station: at three shifts a day, six days a week, one station supports roughly 936 treatment-slots a year. At the blended $331 per-treatment revenue figure used above, that's approximately $310,000 of annual revenue per station before any capacity is lost to no-shows, holidays, or maintenance downtime. Multiplying that per-station figure by realistic utilisation, typically 80-90% once a clinic is past its first year, gives a far more defensible revenue forecast than applying a national average revenue-per-clinic figure to a facility of a different size.

It's also worth separating acute kidney injury (AKI) treatment from chronic ESRD dialysis in a business plan's revenue section, because CMS pays for AKI dialysis under a different payment track than the ESRD PPS bundled rate. Clinics with a hospital-partnership referral arrangement can pick up meaningful incremental volume treating hospitalised AKI patients who need short-term dialysis before either recovering kidney function or transitioning to chronic ESRD care, and this revenue line is frequently left out of generic templates because it depends on a hospital relationship most first-time founders have not built yet.

Certification, Licensing & Legal Requirements

United States

• CMS ESRD certification: submit form CMS-3427 to your State Survey Agency or a CMS-approved accreditation organisation, then pass a survey against the ESRD Conditions for Coverage
• Certificate of Need (CON): required in 13 states before you can build, expand, or operate a renal dialysis facility; approval typically takes 6–18 months and must be confirmed, or confirmed unnecessary, before signing a lease or ordering equipment
• Medicare provider enrollment: via PECOS or the 60-page CMS-855A form, filed with your Medicare Administrative Contractor
• Medical director requirements: board-certified physician oversight, per CMS clarification guidance issued in QSO-24-16-ESRD
• State-specific nursing and PCT staffing ratios, documented in the facility's own policies and tested during survey

United Kingdom

• Register with the Care Quality Commission (CQC) as an independent acute single-specialty provider; registration fee is £1,743 for a single location
• Submit a Statement of Purpose covering aims, objectives, and services offered
• Enhanced DBS checks for the registered manager and all clinical staff
• Policies covering infection control, safeguarding, and complaints handling, reviewed against CQC's published independent-healthcare dialysis inspection framework
• CQC review of the full application typically takes 8–12 weeks

Canada

Canadian dialysis licensing runs through provincial rather than federal authority. In Ontario, for example, facilities are licensed under the Integrated Community Health Services Centres Act, 2023 (ICHSCA), with licences issued for terms of up to five years. Maintenance dialysis in Canada is delivered almost entirely through provincial Renal Programs funded by the Ministry of Health or a dedicated renal agency, which means the standalone commercial clinic model common in the US and UK is far less typical there. Founders considering Canada should budget for a longer, partnership-driven approval process rather than a straightforward independent registration. Australia follows a similar state-based pattern: renal facility design and staffing must meet standards set by each state health department, and organisations are expected to confirm local licensing requirements before finalising an operational plan, since ratios and design guidelines can vary meaningfully between states.

Insurance & Compliance

Beyond facility licensing, a dialysis business plan should address three further compliance areas that lenders and CON reviewers routinely ask about. Professional and general liability insurance for a dialysis facility is materially higher than for a general outpatient clinic given the acuity of ESRD patients and the invasive nature of vascular access, and most independent clinics carry coverage well into seven figures. HIPAA compliance requires a documented security risk assessment and a business associate agreement with every vendor touching patient data, including the EHR provider and any billing outsourcer. And anti-kickback and Stark Law exposure is a live issue in nephrology specifically, because physician ownership stakes in a dialysis facility they also refer patients to are heavily scrutinised; most bespoke plans for physician-founded clinics include a dedicated compliance section addressing referral relationships explicitly, which is exactly the kind of detail a generic template omits.

One further practical point: most states require the clinical staff hired ahead of your CMS survey to already hold current certifications, including CPR/BLS and, for many roles, the Certified Clinical Hemodialysis Technician (CCHT) credential for patient care technicians. Building a hiring timeline that accounts for candidates who need to sit a certification exam before their start date, rather than assuming a fully certified applicant pool, is a small planning detail that consistently trips up first-time operators against a fixed CMS survey date.

Common Mistakes First-Time Operators Make

• Starting build-out before CON or CMS certification is secured. A 6-18 month approval window in CON states means idle debt service if construction starts too early. Confirm approval status before signing a lease.
• Understaffing nurse and PCT ratios to protect margin. Chronic understaffing is a documented industry-wide issue that drives the burnout and turnover cycle covered by outlets like the National Kidney Foundation, and it is one of the fastest routes to a failed survey.
• Underwriting the plan on commercial-insurance rates. With most patients covered by Medicare or Medicaid at the $273.82 bundled rate, a plan built around the $1,041 commercial figure will chronically overstate revenue.
• Under-investing in the water treatment system and its maintenance contract. Water quality failures are among the most common reasons a facility fails its CMS or state survey.
• Having no bench of relief nursing staff. A single resignation without a pre-cleared replacement can force a facility out of ratio compliance within a single pay period.
• Treating site selection as an afterthought. Choosing a location for its street visibility rather than its patient transport access and plumbing/electrical capacity routinely adds unplanned tens of thousands of dollars to the build-out budget once construction begins.
• Delaying the referral network until after opening. Because most dialysis patients arrive via nephrologist referral rather than self-directed search, a clinic that waits until its opening date to start building relationships with local nephrology practices and hospital discharge planners typically spends its first two quarters under-capacity.

Most of these mistakes share a root cause: modelling the best case rather than the typical case. A credible dialysis business plan should show the Medicare-heavy payer mix, the realistic survey timeline, and a staffing plan with built-in redundancy, not the version of the business that only works if everything goes right. Lenders and CON reviewers have seen enough dialysis applications to recognise an overly optimistic plan immediately, and a plan that explicitly addresses these failure modes tends to read as more, not less, credible.

A useful discipline when drafting this section yourself is to write down the single biggest assumption behind each number in your financial model, then ask what happens if that assumption is wrong by 20%. If a 20% miss on payer mix, caseload, or staffing cost turns a viable clinic into an unviable one, the plan needs a wider margin of safety before it goes in front of a lender, not a more optimistic restatement of the same assumption.

Sample Business Plan Preview

Here's an extract from a business plan written by our team for a dialysis clinic client, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your clinic at a glance, written to hold a lender's or investor's attention in the first minute
• Company Overview — Legal structure, ownership, medical director arrangement, and facility location
• Industry Analysis — Market size, reimbursement trends, and the CON/CMS regulatory picture in your state
• Customer Analysis — Patient demographics, referral sources, and payer-mix assumptions
• Competitor Analysis — Local competitive mapping against national chains and independent clinics
• Marketing Plan — Nephrology referral partnerships, hospital discharge planning relationships, and patient acquisition
• Operations Plan — Shift scheduling, staffing ratios, and equipment maintenance workflows
• Management Team — Medical director, clinical lead, and administrative hires planned

The optional Financial Forecast add-on, included in our $300/£250 and $1,000/£800 packages, provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements built around your specific payer mix and station count. If you're comparing this against a closely related facility model, our Kidney Dialysis Center Business Plan Template covers the larger-scale, multi-site version of this same build.

For a dialysis clinic specifically, we also tailor the Industry Analysis section to reference the CMS ESRD Prospective Payment System rate you'll actually be reimbursed at, the CON status of your specific state, and the local nephrology referral network rather than generic healthcare-sector statistics. That level of specificity is what separates a plan that reads as researched from a plan that reads as templated, and it's usually the first thing an SBA underwriter or CON reviewer notices when comparing applications.

Frequently Asked Questions